Literature DB >> 33670052

Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).

Fumi Miyagawa1, Hideo Asada1.   

Abstract

Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) is a severe type of adverse drug eruption associated with multiorgan involvement and the reactivation of human herpesvirus 6, which arises after prolonged exposure to certain drugs. Typically, two waves of disease activity occur during the course of DIHS/DRESS; however, some patients experience multiple waves of exacerbation and remission of the disease. Severe complications, some of which are related to cytomegalovirus reactivation, can be fatal. DIHS/DRESS is distinct from other drug reactions, as it involves herpes virus reactivation and can lead to the subsequent development of autoimmune diseases. The association between herpesviruses and DIHS/DRESS is now well established, and DIHS/DRESS is considered to arise as a result of complex interactions between several herpesviruses and comprehensive immune responses, including drug-specific immune responses and antiviral immune responses, each of which may be mediated by distinct types of immune cells. It appears that both CD4 and CD8 T cells are involved in the pathogenesis of DIHS/DRESS but play distinct roles. CD4 T cells mainly initiate drug allergies in response to drug antigens, and then herpesvirus-specific CD8 T cells that target virus-infected cells emerge, resulting in tissue damage. Regulatory T-cell dynamics are also suggested to contribute to the diverse symptoms of DIHS/DRESS. However, the pathomechanisms of this complex disease remain largely unknown. In particular, how viral infections contribute to the pathogenesis of DIHS/DRESS and why autoimmune sequelae arise in DIHS/DRESS are yet to be elucidated. This review describes the clinical features of DIHS/DRESS, including the associated complications and sequelae, and discusses recent advances in our understanding of the immunopathogenic mechanisms of DIHS/DRESS.

Entities:  

Keywords:  autoimmune disease; drug reaction with eosinophilia and systemic symptoms; drug-induced hypersensitivity syndrome; herpesvirus; pathomechanism; severe cutaneous adverse reactions

Mesh:

Substances:

Year:  2021        PMID: 33670052      PMCID: PMC7927043          DOI: 10.3390/ijms22042147

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  75 in total

1.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.

Authors:  Patricia T Illing; Julian P Vivian; Nadine L Dudek; Lyudmila Kostenko; Zhenjun Chen; Mandvi Bharadwaj; John J Miles; Lars Kjer-Nielsen; Stephanie Gras; Nicholas A Williamson; Scott R Burrows; Anthony W Purcell; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Drug-induced hypersensitivity syndrome associated with cytomegalovirus reactivation: immunological characterization of pathogenic T cells.

Authors:  Hideo Hashizume; Masahiro Takigawa
Journal:  Acta Derm Venereol       Date:  2005       Impact factor: 4.437

3.  Involvement of Human Herpesvirus 6 Infection in Renal Dysfunction Associated with DIHS/DRESS.

Authors:  Kazuya Miyashita; Chinatsu Shobatake; Fumi Miyagawa; Nobuhiko Kobayashi; Rie Onmori; Shinsuke Yonekawa; Kaori Tanabe; Kenji Kawate; Kohei Morita; Hideo Asada
Journal:  Acta Derm Venereol       Date:  2016-01       Impact factor: 4.437

4.  Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS).

Authors:  Fumi Miyagawa; Yuki Nakamura; Kazuya Miyashita; Hiroshi Iioka; Yukiko Himuro; Kohei Ogawa; Chizu Nishimura; Mitsuko Nishikawa; Yasuhiro Mitsui; Yumiko Ito; Rie Ommori; Yasuko Mori; Hideo Asada
Journal:  J Dermatol Sci       Date:  2016-05-09       Impact factor: 4.563

5.  Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.

Authors:  Tai-Ming Ko; Wen-Hung Chung; Chun-Yu Wei; Han-Yu Shih; Jung-Kuei Chen; Chia-Hsien Lin; Yuan-Tsong Chen; Shuen-Iu Hung
Journal:  J Allergy Clin Immunol       Date:  2011-09-14       Impact factor: 10.793

Review 6.  Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

Authors:  H Bocquet; M Bagot; J C Roujeau
Journal:  Semin Cutan Med Surg       Date:  1996-12

7.  Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome.

Authors:  V Descamps; F Bouscarat; S Laglenne; E Aslangul; B Veber; D Descamps; J L Saraux; M J Grange; M Grossin; E Navratil; B Crickx; S Belaich
Journal:  Br J Dermatol       Date:  1997-10       Impact factor: 9.302

8.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

9.  Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome.

Authors:  G Choquet-Kastylevsky; L Intrator; C Chenal; H Bocquet; J Revuz; J C Roujeau
Journal:  Br J Dermatol       Date:  1998-12       Impact factor: 9.302

10.  Correlation Between Expression of CD134, a Human Herpesvirus 6 Cellular Receptor, on CD4+ T cells and Th2-type Immune Responses in Drug-induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Fumi Miyagawa; Yuki Nakamura-Nishimura; Yushi Kanatani; Hideo Asada
Journal:  Acta Derm Venereol       Date:  2020-03-31       Impact factor: 3.875

View more
  7 in total

Review 1.  Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS)/Drug-Induced Hypersensitivity Syndrome (DiHS)-Readdressing the DReSS.

Authors:  Hannah Stirton; Neil H Shear; Roni P Dodiuk-Gad
Journal:  Biomedicines       Date:  2022-04-26

2.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

3.  Fulminant Type 1 Diabetes Mellitus Associated With Drug Hypersensitivity and Epstein-Barr Virus Infection: A Case Report.

Authors:  Xing-Yu Chen; Cong Wang; Shizhi Chen; Mingyuan Tian; Xin Wang; Lili Zhang
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

4.  Drug hypersensitivity syndrome induced by sulfasalazine: A case report.

Authors:  Dong-Hui Chen; Hai-Rong Zhou; Yong-Gang Zhang; Guan-Yuan Shen; Chong Xu; Chun-Li Guan
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

5.  Current Understanding of Immunological Skin Diseases: Atopic Dermatitis, Generalized Anhidrosis, and Drug Hypersensitivity.

Authors:  Hideo Hashizume
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

6.  Cutaneous Adverse Drug Reactions (CADRs)-Statistical Analysis of the Causal Relationship between the Drug, Comorbidities, Cofactors, and the Cutaneous Reaction-A Single-Centered Study.

Authors:  Natalia Machoń; Julia Lewandowska; Natalia Zdanowska; Waldemar Placek; Agnieszka Owczarczyk-Saczonek
Journal:  Int J Environ Res Public Health       Date:  2022-06-29       Impact factor: 4.614

7.  Case report: Drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti-interferon-γ autoantibody-associated immunodeficiency.

Authors:  Yuxue Nie; Han Wang; Xiying Dong; Siqi Pan; Ting Zhang; Jun Ran; Ying Zhang; Junping Fan; Linqi Zhang; Jinglan Wang
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.